Lipistad

Atorvastatin, the active ingredient in Lipistad, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol and triglyceride levels and is used in adults at risk of cardiovascular disease, and is marketed in the European Union.

GNH USA supplies Lipistad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin is indicated for disorders of lipid metabolism and for cardiovascular risk reduction. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol levels. - Primary prevention of cardiovascular disease: lowers the risk of myocardial infarction, stroke and cardiovascular death in high‑risk patients. - Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established coronary artery disease. - Mixed dyslipidemia: improves the lipid profile by decreasing triglycerides and increasing high‑density lipoprotein (HDL) cholesterol.

Atorvastatin may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Muscle aches or weakness - Headache - Nausea - Elevated liver enzymes

Serious or Rare Side Effects: - Rhabdomyolysis - Acute liver injury - Severe allergic reactions (e.g., angioedema)

When prescribing Lipistad, several safety considerations should be observed. - Pregnancy: contraindicated; teratogenic risk (Category X). - Liver disease: avoid in active hepatic impairment. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Drug interactions: review concomitant medications for potential interactions. - Monitoring: periodic assessment of liver enzymes and lipid profile recommended. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Atorvastatin interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can markedly increase atorvastatin exposure. - Gemfibrozil: increases risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum hydroxide): may reduce absorption, affecting efficacy. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: slight increase in serum levels may occur.